Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Prime Medicine (PRME) Return on Sales (2025)

Historic Return on Sales for Prime Medicine (PRME) over the last 2 years, with Q3 2025 value amounting to 43.13%.

  • Prime Medicine's Return on Sales rose 2081500.0% to 43.13% in Q3 2025 from the same period last year, while for Sep 2025 it was 33.39%, marking a year-over-year increase of 2406700.0%. This contributed to the annual value of 65.67% for FY2024, which is N/A changed from last year.
  • Per Prime Medicine's latest filing, its Return on Sales stood at 43.13% for Q3 2025, which was up 2081500.0% from 47.17% recorded in Q2 2025.
  • Over the past 5 years, Prime Medicine's Return on Sales peaked at 19.37% during Q4 2024, and registered a low of 367.92% during Q2 2024.